Is XXXX the most radiocurable type of @entity2 ?

@entity1 @entity4153 @entity5 @entity957 @entity2 @entity1149 @entity152 @entity3 @entity420
Radiation therapy is widely considered the primary treatment for inoperable "non-small" cell @entity2 . In clinical investigations, distinction has been infrequent among the histopathologic subtypes of @entity4153 . Studies have shown significant differences between @entity957 and @entity5 ; @entity5 has a greater propensity for extrathoracic dissemination, especially to the brain, and it is less curable by resection when regional lymph node @entity3 are present. No differences have been documented between @entity420 and @entity152 . A retrospective study was undertaken to determine the results of definitive radiation therapy by histopathologic subtype of @entity1149 . Between July 1977 and April 1983, 134 @entity1 with @entity1149 underwent definitive radiation therapy with curative intent. All @entity1 had performance status scores of 80 to 100 (Karnofsky), and received minimum total doses within the @entity5 of 60 Gy in 6 to 7 weeks, five fractions per week. The median period of observation was 63 months. Ninety @entity1 had @entity957 ; 44 had @entity5 . The two groups of @entity1 were comparable in respect to age and Stage; there were significantly more @entity1 with @entity5 (27%) than with @entity957 (13%). The median survival for @entity1 with @entity957 was 11.5 months; the 2 and 4 year survival rates were 21 and 7%, respectively. The median survival for @entity1 with @entity5 was 18 months; 2 and 4 year survival rates were 38 and 23%, respectively. Comparison of the overall survival experience did not show a significant difference between the two cell types (p = .12 using Gehan's generalized Wilcoxon test). However, comparison of the proportion of @entity1 with @entity5 surviving 18 months (50%) was significantly higher (p = .02) than that with @entity957 (30%). A small body of data from the literature also suggests a better long-term prognosis for @entity5 . This observation requires confirmation from large trials with histopathologic review. If it is confirmed, there are important implications for therapeutic strategies in future clinical investigations of inoperable @entity2 .
